Sol-Gel Technologies Ltd.
NASDAQ:SLGL · NASDAQ Global Market
-$1.86 today
Vol 0.01M · Avg 0.04M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-26.9%
avg -9.9%
ROIC
-31.1%
avg -84.4%
ROA
-20.5%
avg -71.4%
Analysis
ROA is currently the strongest return metric at -20.5% versus its period average of -71.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Glezin | Chief Business Officer | $288,000.00 | — | 43 | $1,500.00 | 0.05% |
Itzik Yosef | Chief Operating Officer | $280,000.00 | — | 50 | $0.00 | <0.01% |
Eyal Ben-Or | Chief Financial Officer | $267,000.00 | — | 42 | $0.00 | <0.01% |
Moshe Arkin | Chief Executive Officer & Executive Chairman | — | — | 73 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
28
$7.07M
Sells
0
$0.00
Net Sentiment
+$7.07M
Net buying
Most Active
Opaleye Management Inc.
28 transactions
1–10 of 28
Analysis
Insiders reported 28 buys worth $7.07M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $7.07M. Opaleye Management Inc. was the most active insider with 28 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +77.1% (12yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +77.1% (12yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Tiziana Life Sciences Ltd
NASDAQ:TLSA
$65.37M
Clene Inc.
NASDAQ:CLNN
$60.20M
OKYO Pharma Limited
NASDAQ:OKYO
$58.32M
Anebulo Pharmaceuticals, Inc.
ANEB
$19.37M
Who manages SLGL?
Sol-Gel Technologies Ltd. (SLGL) lists 4 active executives. The top listed executive is Michael Glezin, Chief Business Officer.
Are SLGL insiders buying or selling?
Recent insider activity shows net buying of $7.07M.
Explore More
Continue the stock analysis
Jump to another research area for this company.